zacks.com · 2 jul

Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.

businesswire.com · 1 jul

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT.

reuters.com · 1 jul

US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two

The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy in children as ​young as two with inherited blood disorders, including ‌sickle cell disease, the first such treatment cleared for this age group.

fool.com · 1 jul

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management.

seekingalpha.com · 30 jun

Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech

Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027.

fool.com · 29 jun

Why Vertex Stock Is Rising Today

One firm sees room for this tech stock to run.

fool.com · 27 jun

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.

businesswire.com · 24 jun

Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project

HOUSTON--(BUSINESS WIRE)-- #BaseOils--Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company's existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III.